« Förderinformationen
Sie verwenden einen sehr veralteten Browser und können Funktionen dieser Seite nur sehr eingeschränkt nutzen. Bitte aktualisieren Sie Ihren Browser. http://www.browser-update.org/de/update.html
Innovative Medicines Initiative 2 (IMI2) Joint Undertaking
Aktualität:
bis 01.01.2018
Fördergeber:
Europäische Kommission : Horizon 2020
Research related to the future of medicine should be undertaken in areas where societal, public health and biomedical industry competitiveness goals are aligned and require the pooling of resources and greater collaboration between the public and private sectors, with the involvement of small and medium-sized enterprises (SMEs).
The scope of the initiative should be expanded to all areas of life science research and innovation.
The areas should be of public health interest, as identified by the World Health Organisation (WHO) report on priority medicines for Europe and the World.
The initiative should therefore seek to involve a broader range of partners, including mid-sized companies.
from different sectors e.g. biomedical imaging, medical information technology, diagnostic and/or animal health industries. Involving the wider community in this way should help to advance the development of new approaches and technologies for the prevention, diagnosis and treatment of diseases with high impact on public health.

- IMI2-2016-10-01: Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
- IMI2-2016-10-02: How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer
- IMI2-2016-10-03: Improving the care of patients suffering from acute or chronic pain
- IMI2-2016-10-04: Creation of a pan-European Paediatric Clinical Trials Network
- IMI2-2016-10-05: Biomanufacturing 2020: Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
- IMI2-2016-10-06: Unlocking the Solute Carrier Gene-Family for Effective New Therapies (Unlock SLCs)
- IMI2-2016-10-07: Patient perspectives in medicines lifecycle
- IMI2-2016-10-08: Personalised medicine approaches in autism spectrum disorders

Further information n:
http://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche16-10-imi2-ju_en.pdf
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2016-10-two-stage.html#c,topics=callIdentifier/t/H2020-JTI-IMI2-2016-10-two-stage/1/1/1/default-group&callStatus/t/Forthcoming/1/1/0/default-group&callStatus/t/Open/1/1/0/default-group&callStatus/t/Closed/1/1/0/default-group&+identifier/desc